skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Infliximab in the treatment of plaque type psoriasis

Review

(6603) Views  (981) Full article downloads

Authors: Rosita Saraceno, Andrea Saggini, Lucia Pietroleonardo, Sergio Chimenti

Published Date April 2009 Volume 2009:2 Pages 27 - 37
DOI: http://dx.doi.org/10.2147/CCID.S3413

Rosita Saraceno, Andrea Saggini, Lucia Pietroleonardo, Sergio Chimenti

Department of Dermatology, University of Rome Tor Vergata, Rome, Viale Oxford 81, Rome, Italy

Abstract: Psoriasis is a chronic and immunomediated skin disease characterized by erythematous scaly plaques. Psoriasis affects approximately 1% to 3% of the Caucasian population. Tumor necrosis factor alpha (TNF-α) is a proinflammatory cytokine that plays a critical role in the pathogenesis of psoriasis. Infliximab is an anti-TNF-α drug widely used for the treatment of plaque type psoriasis and psoriatic arthritis. Controlled clinical trials demonstrated that infliximab is characterized by a high degree of clinical response in moderate to severe plaque psoriasis. Moreover infliximab showed rapid efficacy in nail psoriasis which represents a therapeutic challenge for dermatologists and a relevant source of distress for patients with plaque psoriasis. This anti-TNF-α has an encouraging safety profile, especially as long as physicians are watchful in prevention and early diagnosis of infections and infuse reactions. The efficacy, tolerability and safety profiles suggest infliximab as a suitable anti-psoriatic drug in the long-term treatment of a chronic disease such as plaque-type psoriasis.

Keywords: psoriasis, nail psoriasis, infliximab, long-term treatment








Readers of this article also read:

Itch in psoriasis: epidemiology, clinical aspects and treatment options
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Management of superficial basal cell carcinoma: focus on imiquimod
An update on the management of acne vulgaris
Review of soft tissue augmentation in the face
Novel topical therapy for mild-to-moderate plaque psoriasis: focus on calcitriol
Perception of risk and benefit in patient-centered communication and care
Steroid response pattern and outcome of pediatric idiopathic nephrotic syndrome: a single-center experience in northwest Iran
The relationship between deliberate self-harm behavior, body dissatisfaction, and suicide in adolescents: current concepts
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University

  • American Acne and Rosacea Society

    The American Acne and Rosacea Society (AARS), is a 501(c)(6) non-profit organization dedicated to elevating the understanding and treatment of acne and rosacea.